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Clustering of Autoimmune Diseases (CAD) is now emerging as a novel clinical entity within monogenic immune
defects with a high familial occurrence. Aim of this study is to evaluate the regulatory mechanisms governing cell
survival, paying a particular attention to Fas-induced apoptosis, in a cohort of 23 children affected with CAD. In 14
patients, Fas stimulation failed to induce cell apoptosis and in 1 case it was associated with Fas gene mutation. Our
study highlights the importance to evaluate cell apoptosis in the group of children with CAD, which, with this
regard, represents a distinct clinical entity.
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Even though distinct autoimmune disorders may be
associated in the same individual [1,2], only rare patients
exhibit a clear clustering of distinct diseases, which are
indicative of a common poly-reactive autoimmune
process [3]. Along with environmental factors, a genetic
susceptibility represents a well established feature in the
predisposition of individuals to certain autoimmune dis-
eases, including the association with certain specific
HLA and complement polymorphic variants. However,
the intimate pathogenic mechanism of autoimmunity
still remains to be unraveled. Alterations of homeostatic
mechanism resulting in an abnormal lymphocyte accu-
mulation, autoimmunity or lymphoid malignancies, have
now emerged as a novel pathogenic mechanism under-
lying intense poly-reactive auto-reactions [4-6]. Recent
evidence indicates that, in a few cases, Clustering of
Autoimmune Disorders (CAD) may represent unique
model of monogenic autoimmune disorder or a sign of
congenital immunodeficiencies [7-9]. Hematologic auto-
immune disorders associated with non-malignant lymph
adenopathy are the prominent clinical features of the* Correspondence: pignata@unina.it
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whose molecular characterization leads to define five
distinct entities on the basis of the location of the defect
in the Fas signaling cascade [3]. However, in a large
group of ALPS patients the molecular defect still
remains to be identified. We recently reported on a
group of children affected with CAD who exhibited a
high prevalence of familial cases [10].
Aim of this study is to evaluate Fas-induced apoptosis
in this cohort of patients.
CAD was defined by the presence of at least three dis-
tinct organ-specific or systemic immune disorders in the
same individual [10]. The predominant autoimmune dis-
eases in these 23 patients (14 female) were rheumatoid
arthritis, type 1 diabetes, autoimmune thyroiditis and
celiac disease, as previously described in detail [10]. Fas-
mediated lymphocyte apoptosis was evaluated on acti-
vated T-cell lines obtained by treating peripheral blood
mononuclear cells (PBMC) with phytohemagglutinin
(PHA) at days 0 (1 μg/mL) and 12 (0.1 μg/mL), as previ-
ously reported [2,11]. Fas function was defined defective
when cell survival was higher than 78%, which was the
95th percentile of the response displayed by normal
controls.
Fas-induced cell death in PHA-derived T-cell lines was
abnormal in 14 of the 23 patients (60%) (Figure 1). Fasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 T-cell sensitivity to Fas induced cell death in CAD patients. Peripheral blood T cells were stimulated by PHA and cultured in the
presence of rIL-2 prior to further stimulation through Fas receptor. Results were expressed as relative cell survival percentage, calculated as
follows: (total live cell count in the assay wells/total live cell count in the untreated samples) x 100. Shaded area indicates the range of normal
values (i.e. the range between the 5th and the 95th percentile of normal controls values).
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direct immunofluorescence on the same day in which
Fas function was assessed and was expressed always at
comparable levels than in controls. In the 14 patients
with defective Fas-induced apoptosis, sequencing ana-
lysis of the Fas gene (TNFRSF6) revealed a 2 base dele-
tion in exon 4 (g410-411delCT) in one patient (Pt#14).
In other patients, 5 already described silent polymorph-
isms were also found, 2 of them in the 5’ UTR region, 2
in the coding region, and 2 in the intronic region (IVSIII
nt 46, IVSV nt 82).
In this study we report on a functional impairment of
cell death, induced through Fas triggering, in the 60% of
patients affected with CAD, thus suggesting some over-
lap with ALPS [3,4]. Only in 1 patient the functional al-
teration was associated with gene mutation.
A genetic cause of certain complex autoimmune syn-
dromes has also been established in Autoimmune
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
syndrome (APECED) [12,13]. However, in our patients
the diagnostic criteria for this syndrome were missing.
Apoptosis is a complex process that plays a central
mechanism in the homeostasis of immune response and
in the regulation of the cellular differentiation [14,15]. It
is triggered through 2 major signaling pathways [16-18].
The first involves death receptor family members, such
as CD95/Fas, TRAILR1-2, TNF-R1, which in turn acti-
vate the caspases cascade, resulting in caspase 3 activa-
tion [19]. The process results in the proteolytic
cleaveage of nuclear and cytoplasmic substrates, and the
subsequent cellular disassembly [20,21]. Along with this
Fas-dependent pathway, several stimuli, such as DNA
damage, metabolic imbalance, growth factor deprivation,
or cell cycle perturbation activates the alternativemitochondrial apoptotic pathway [18]. This implies that
a very high number of signaling molecules involved in
the processes may be altered causing an ALPS-like
phenotype [22].
In conclusion, our study highlights the importance to
evaluate Fas-induced cell survival in the clinical ap-
proach to patients with CAD even though the exact role
of Fas-induced cell death abnormalities in the pathogen-
esis of CAD remains to be fully elucidated. The high
prevalence of familiarity in such cases would suggest an
inheritable pathogenetic mechanism, even though in
previous studies it has been shown that there is no cor-
respondence in the clinical phenotype among different
family members indicating a role for several environ-
mental and genetic factors [10,23].
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